Journal of the Society for Cardiovascular Angiography & Interventions · 2025
Evaluation of Long-Term Key Outcomes and Safety in Pulmonary Embolism: The EKOS-PE Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sayfo Sameh, Pickering Taylor, Moubarak Ghadi, McCullough Kyle M, Dorton Cody W, AboHajar Mohamad Bader, Prasad Tanushree, Parro Colleen, Raghunathan Maya, Bhavikati Pratham, Gupta Swapnil, Shah Madhura Kapil, DiMaio J Michael, Thomas Sibi, Al-Azizi Karim, Gable Dennis, Kedora John, Dib Chadi, Potluri Srini, Szerlip Molly, George Timothy J, Rosol Zachary P, Banerjee Subhash
Аннотация
BACKGROUND: Pulmonary embolism (PE) is a major cause of morbidity and mortality, particularly in massive and submassive cases that lead to right ventricular (RV) strain and long-term complications. The EkoSonic Endovascular System (EKOS) offers a catheter-directed thrombolytic treatment option for patients with contraindications to systemic thrombolysis, but data on long-term outcomes remain limited. We aimed to evaluate long-term mortality, RV function, and quality of life (QoL) in patients with massive or submassive PE who were treated with EKOS therapy.
METHODS: The EKOS-PE is a retrospective cohort study of 137 patients with massive or submassive PE who underwent EKOS therapy within a single health care system from 2020 to 2024. The primary outcome was all-cause mortality; secondary outcomes included changes in the RV-to-left ventricular (LV) (RV/LV) ratio, residual RV dysfunction, and QoL as assessed using the Pulmonary Embolism Quality of Life questionnaire.
RESULTS: All-cause mortality was 7.2% at a mean follow-up of 26.5 ± 17.2 months. During the index hospitalization, 1 retroperitoneal bleed (0.7%) and 1 ischemic stroke (0.7%) were observed. The mean RV/LV ratio decreased from 1.13 ± 0.24 to 0.83 ± 0.19 (P < .01). No residual RV dysfunction was evident in 105 (75.5%) patients, whereas 16 (11.5%) exhibited moderate to severe residual dysfunction. Of 52 respondents who completed the QoL survey at a mean follow-up of 37.2 ± 12.1 months, minimal residual symptoms, limited functional interference, and improved perceived lung health were reported.
CONCLUSIONS: The EKOS therapy is associated with significant long-term improvement in RV function, low mortality, and favorable perceived QoL, supporting its use in massive and submassive PE, aligning with current guideline recommendations for high-risk patients.
METHODS: The EKOS-PE is a retrospective cohort study of 137 patients with massive or submassive PE who underwent EKOS therapy within a single health care system from 2020 to 2024. The primary outcome was all-cause mortality; secondary outcomes included changes in the RV-to-left ventricular (LV) (RV/LV) ratio, residual RV dysfunction, and QoL as assessed using the Pulmonary Embolism Quality of Life questionnaire.
RESULTS: All-cause mortality was 7.2% at a mean follow-up of 26.5 ± 17.2 months. During the index hospitalization, 1 retroperitoneal bleed (0.7%) and 1 ischemic stroke (0.7%) were observed. The mean RV/LV ratio decreased from 1.13 ± 0.24 to 0.83 ± 0.19 (P < .01). No residual RV dysfunction was evident in 105 (75.5%) patients, whereas 16 (11.5%) exhibited moderate to severe residual dysfunction. Of 52 respondents who completed the QoL survey at a mean follow-up of 37.2 ± 12.1 months, minimal residual symptoms, limited functional interference, and improved perceived lung health were reported.
CONCLUSIONS: The EKOS therapy is associated with significant long-term improvement in RV function, low mortality, and favorable perceived QoL, supporting its use in massive and submassive PE, aligning with current guideline recommendations for high-risk patients.